Liontown Limited stock jumps 4.6% as lithium demand outlook firms; Jan 29 report next

Liontown Limited stock jumps 4.6% as lithium demand outlook firms; Jan 29 report next

Sydney, January 7, 2026, 17:58 AEDT — Market closed

  • Liontown ended up 4.6% at A$2.03 after trading as high as A$2.04
  • A battery storage-led lift in lithium demand is pulling investors back into the sector
  • Next catalyst is Liontown’s December-quarter report due Jan. 29

Liontown Limited (ASX:LTR) shares closed up 4.6% at A$2.03 on Wednesday, up from a previous close of A$1.94. They traded between A$1.92 and A$2.04, leaving the miner near the top of its 52-week range and about A$6 billion in market value. Google

The move comes as investors chase lithium miners on signs the market’s long slump is easing. “The data centre building boom in China and globally has also driven growing power storage demand for lithium,” said Jinyi Su, a Wuxi-based analyst at consultancy Fubao. UBS data show lithium demand for energy storage jumped 71% in 2025 and is forecast to rise 55% in 2026, while some market forecasts point to a swing to deficits this year after a 2025 surplus. Reuters

Market Index said brokers have also sharpened their focus on grid-scale batteries, arguing stronger energy storage demand can tighten the market before new supply responds. The publication flagged Liontown’s Kathleen Valley operation in Western Australia — alongside larger peers such as Pilbara Minerals, Mineral Resources and IGO — as among the ASX names most exposed to a firmer pricing backdrop for spodumene concentrate, the lithium-rich ore used to make battery chemicals. Market Index

For Liontown, traders will look for evidence that stronger lithium pricing is filtering into realised sales prices and cash generation as it continues to ramp operations.

With the market closed, chart watchers will test whether the stock can hold above A$2.00 after Wednesday’s push into new highs, rather than slipping back into the mid-A$1.90s where buyers last stepped in.

But the rally leans on a still-fragile commodity turn. Lithium prices can retreat quickly if producers restart idled capacity faster than demand grows, or if buyers run down inventories instead of returning to spot purchases.

Stock Market Today

  • Summit Therapeutics valuation under the microscope after share strength; P/B at 74.8x, DCF fair value $217.67
    January 7, 2026, 8:37 PM EST. Summit Therapeutics (SMMT) rose 1.9% on the day and 8.7% over the week, though longer-term returns remain uneven: 30 days up 2.07%, 90 days down 16.07%, and a three-year total shareholder return that highlights patient holders' gains despite near-term momentum cooling. On a P/B basis, the stock trades at 74.8x price against a US$19.01 share price, far above the industry average of 2.7x and a peer average of 11.2x, signaling the market expects a stronger future than the balance sheet implies. A DCF model puts fair value at US$217.67 versus last close of US$19.01, suggesting potential discount based on cash flow scenarios. The narrative flags OVERVALUED P/B and UNDERVALUED DCF; risk remains, including ongoing net losses of US$921.617 and potential ivonescimab trial failures.
Mineral Resources shares slip from fresh 52-week high as lithium rally keeps investors on edge
Previous Story

Mineral Resources shares slip from fresh 52-week high as lithium rally keeps investors on edge

4DMedical shares jump on UC San Diego Health CT:VQ rollout as market eyes next catalyst
Next Story

4DMedical shares jump on UC San Diego Health CT:VQ rollout as market eyes next catalyst

Go toTop